Document:

Exhibit 10.1

    
      

    

    Exhibit
      10.1

     

    
      JOINT
        DEVELOPMENT AND MARKERTING AGREEMENT

      

       

      This
        Joint Development and Marketing Distribution Agreement (“Agreement”) is entered
        into this 18th day of April, 2007 (“Effective Date”), by and between Applied DNA
        Sciences, Inc. a Nevada corporation with its principal place of business
        at 25
        Health Sciences Dr, Stony Brook NY 11790 (“ADNAS”) and IIMAK, a Delaware
        corporation with its principal place of business at 310 Commerce Dr, Amherst,
        NY
        14534,
        (“IIMAK”). 

       

       

      WHEREAS,
        ADNAS
        is in the business of developing, selling and marketing of DNA anti-counterfeit
        and security products;

      

      WHEREAS,
        ADNAS
        owns exclusive rights to certain proprietary technologies involving the
        extraction, recombination, encapsulation, and preservation of botanical DNA,
        (the “DNA Technologies”);

      

      WHEREAS,
        the DNA
        Technologies are used to forensically authenticate products, to detect and
        deter
        counterfeiting, to protect brands and intellectual property assets, to provide
        enhanced security for physical plant, documents, identification cards,
        passports, drivers licenses, currencies, databases and other products and
        applications, and can be embedded into various industrial and consumer products;
        

      

      WHEREAS,
        IIMAK is
        in the business of manufacturing and selling thermal transfer ribbons and
        is an
        established developer, manufacturer, supplier and distributor of thermal
        transfer ribbons and IIMAK has an extensive base of clients and suppliers
        in
        this industry, and 

      

      WHEREAS,
        the
        parties wish to enter into this Agreement to jointly develop and have IIMAK
        exclusively manufacture and market DNA-enhanced thermal transfer ribbons,
        (the
“Products”)

       

      NOW
        THEREFORE,
        in
        consideration of the above recitals and mutual covenants and benefits provided
        herein, the Parties agree as follows: 

      

      1,
        DEFINITIONS. 

      

      For
        purposes of this Agreement, the following terms will have the following
        meanings:

      

      	A.  	
              ”DNA
                Technologies”
                mean the proprietary technologies and know how owned exclusively
                by ADNAS
                involving the extraction, recombination, encapsulation, and preservation
                of botanical DNA and the embedding, implanting or attaching of botanical
                DNA into various products; 

            

       

      
        	B.  	
                
                  “ADNAS
                    Materials” mean DNA taggants and related ADNAS’ products employing
                    the DNA Technologies. 

                

              

         

        
          
            
            

          

          
            1
              of
              12

            
              

            

          

          
            
            

          

        

         

      

      	C.  	
              “IIMAK
                Materials” mean thermal transfer ribbons including any hardware and
                software required to print using the thermal
                ribbons

            

      

      	D.  	
              “Product”
                means thermal transfer ribbons, which utilize and integrate the DNA
                Technologies.

            

      

      	E.  	
              “Profit”
                means the actual amount received by IIMAK for the sale of DNA enhanced
                thermal transfer ribbons less the following deductions to the extent
                that
                such amounts are actually accrued or incurred as to such sales: (a)
                cost
                of goods sold (b) freight, packaging and insurance costs incurred
                in
                transporting the Product to customers (c) quantity, cash and other
                trade
                discounts or rebates actually allowed and taken; (d) customs duties,
                surcharges, taxes and other governmental charges incurred with the
                importation or exportation of Products; and (e) amounts repaid or
                credited
                by reason of rejections, recalls or retroactive price reductions.
                

            

      

      	F.  	
              “Territory”
                means the world.

            

       

             
        2. JOINT
        DEVELOPMENT 

      

      	A.  	
              ADNAS
                and IIMAK agree to work jointly together to develop thermal transfer
                ribbons which incorporate ADNAS’s DNA Technologies taggants for the
                prevention of counterfeiting and diversion.

            

      

      	B.  	
              The
                initial joint development period will be six (6) months (“Initial Joint
                Development”), which can be extended by mutual written agreement. The
                Initial Joint Development period will begin on the Effective Date
                of this
                Agreement. A specific plan detailing each Party’s responsibilities along
                with a timeline for fulfilling these responsibilities is attached
                as
                Appendix A. 

            

      

      	C.  	
              Each
                Party will be responsible for its own costs and expenses during the
                Initial Joint Development period and any extensions to the Initial
                Joint
                Development period thereafter, unless otherwise agreed to in writing
                by
                both parties.

            

       

      
        	D.  	
                
                  For
                    purposes of Product development and/or improvement, IIMAK may
                    request
                    ADNAS to provide samples of ADNAS Materials. ADNAS, at its cost,
                    agrees to
                    provide ADNAS Materials and information as reasonably requested
                    by IIMAK
                    and as necessary for the evaluation, development, manufacturing,
                    marketing
                    or distribution of the Product. IIMAK agrees that the ADNAS Materials
                    and
                    Technologies shall be used only for the purpose of evaluating,
                    developing
                    and manufacturing the Products and shall be used for no other
                    purpose
                    without the prior written consent of ADNAS, and any such use
                    shall be
                    under terms that shall equitably accommodate the financial interests
                    of
                    ADNAS. IIMAK agrees to comply with all reasonable security and
                    chain of
                    custody requirements imposed in writing by ADNAS governing the
                    proper
                    protection, security and control of the ADNAS
                    Materials.

                

              

        
           

          
            
              
              

            

            
              2
                of
                12

              
                

              

            

            
              
              

            

          

           

        

      

      	E.  	
              For
                purposes of Product development and/or improvement and Quality Control,
                ADNAS may request that IIMAK provide samples of IIMAK’s current products
                or materials involving the DNA Technologies. IIMAK, at its cost,
                agrees to
                provide IIMAK products or materials as reasonably requested by ADNAS
                and
                as necessary to the evaluation, testing, development, manufacturing,
                marketing and distribution of the Product. ADNAS agrees that the
                IIMAK
                products and materials shall be used only for the purpose of evaluating
                and developing Products and shall be used for no other purpose without
                the
                prior written consent of IIMAK, and any such use shall be under terms
                that
                shall equitably accommodate the financial interests of IIMAK. ADNAS
                agrees
                to comply with all reasonable security and chain of custody requirements
                imposed in writing by IIMAK governing the proper protection, security
                and
                control of the IIMAK materials. 

            

      

      	F.  	
              To
                the extent either party does not have formal security or chain of
                custody
                requirements, the parties agree to develop mutually acceptable protocols
                for the secure storage and custody of any ADNAS Materials and/or
                IIMAK
                Materials transferred in accordance with this Agreement.
                

            

      

      	G.  	
              Unless
                otherwise agreed, ADNAS and IIMAK will each provide the Materials
                required
                to develop and/or test the Products as samples at no cost to each
                other.
                

            

       

             
        3. INTELLECTUAL PROPERTY AND TRADEMARKS

      

      
        	      A.	
                All
                  inventions developed independently during the Initial Joint Development
                  period or any extensions thereof will be owned solely by the inventing
                  party and the other Party will have no rights to that
                  invention.

              

      

      

      
        	      B.	
                All
                  inventions developed jointly during the Initial Joint Development
                  or any
                  extensions
                  thereto will be assigned to ADNAS. ADNAS will be responsible for
                  all costs
                  associated with filing, prosecuting and maintaining any patents
                  resulting
                  from joint inventions. IIMAK shall provide reasonable assistance
                  in a
                  timely manner to ADNAS at ADNAS’ request.

              

      

      

      
        	      C.	
                IIMAK
                  will receive an exclusive, fully paid up worldwide license to any
                  intellectual property jointly developed during the course of this
                  Agreement. Should this Agreement be terminated, this license will
                  convert
                  to a non- exclusive license. 

              

      

       

      
        
          	      D.	
                  
                    Subject
                      to the terms and conditions of this Agreement, ADNAS grants
                      to IIMAK a
                      non-exclusive license to use ADNAS’ logos and trademarks to be used in
                      association with the Products (“ADNAS Trademarks”) to promote and market
                      the Products, provided that IIMAK’s use of the ADNAS trademarks is in
                      accordance with ADNAS’ then-current trademark usage guidelines. IIMAK
                      acknowledges and agrees that ADNAS owns the ADNAS trademarks
                      and that any
                      and all goodwill derived from the use of the ADNAS trademarks
                      by IIMAK
                      hereunder inures solely to the benefit of ADNAS. IIMAK hereby
                      acknowledges
                      that ADNAS owns all right, title and interest in the ADNAS
                      trademarks,
                      together with the goodwill attaching thereto, that may inure
                      to it in
                      connection with this Agreement or from its use of the Trademarks
                      hereunder. IIMAK will not apply to register any ADNAS trademarks,
                      trade
                      name, service mark or other designation that is confusingly
                      similar to any
                      trademark of ADNAS.

                  

                

        

      

      
         

        
          
            
            

          

          
            3
              of
              12

            
              

            

          

          
            
            

          

        

         

      

             
        4. TERMS OF DISTRIBUTION.

       

      Subject
        to the successful completion of the development of commercially feasible
        Products during the Joint Development period and to the terms and conditions
        of
        this Agreement, IIMAK grant to ADNAS and ADNAS hereby agrees to become the
        exclusive supplier of DNA taggants to IIMAK. ADNAS grants to IIMAK and IIMAK
        hereby accepts exclusive worldwide rights to manufacture and sell thermal
        transfer ribbons containing ADNAS’ DNA markers (Products).

       

      5.
        PAYMENTS.

       

      
        	A.  	
                
                  IIMAK
                    will pay to ADNAS a *** (***) royalty Profit where
                    IIMAK initiates first contact with a potential End
                    User which produces a sale of Product to that End
                    User.

                

              

         

        
          	B.  	
                  
                    IIMAK
                      will pay to ADNAS a *** (***) royalty on Profit where ADNAS initiates
                      first contact with a potential End User which produces a sale of
                      Product to that End User.

                  

                

           

        

      

      	C.  	
              During
                the term of this Agreement, IIMAK shall furnish to ADNAS quarterly
                written
                reports detailing the sales and costs for the previous quarter along
                with
                the payments owed to ADNAS for that fiscal quarter. Quarterly reports
                will
                be due within thirty (30) days after the end of each quarter. Payments
                due
                for that quarter will accompany the quarterly reports. Conversion
                from
                foreign currency, if any, shall be based upon the conversion rate
                published in the Wall Street Journal on the last day of the particular
                quarterly accounting period for which payments are due.
                

            

      

      	D.  	
              ADNAS
                shall have the right, upon prior written notice to IIMAK, not more
                than
                once in IIMAK’s fiscal year, to engage an independent nationally-certified
                auditing firm selected by ADNAS and acceptable to IIMAK, which acceptance
                shall not be unreasonably withheld or delayed, to have access during
                normal business hours of IIMAK as may be reasonably necessary to
                verify
                the accuracy of the reports required to be furnished pursuant to
                this
                Section 5.0 B of this Agreement. If such audit shows any underpayment
                of
                royalties, then within thirty (30) days after Party’s receipt of such
                report, IIMAK shall remit to ADNAS:

            

       

      
        	        (a)	
                the
                  amount of such underpayment; and

              

      

      

      
        	        (b)	
                if
                  such underpayment exceeds five percent (5%) of the total payments
                  owed for
                  the fiscal year then being reviewed, the reasonably necessary fees
                  and
                  expenses of such auditing firm performing the audit. Otherwise,
                  such fees
                  and expenses shall be borne solely by ADNAS. Any overpayment shall
                  be
                  fully creditable against future payments in any subsequent
                  period.

              

      

      
         

        
          
            
            

          

          
            4
              of
              12

            
              

            

          

          
            
            

          

        

         

      

      	E.  	
              The
                records required under this Section 5.0 shall be maintained and available
                for inspection for a period of five (5) years following the calendar
                quarter to which they pertain. This Section 5.0D shall survive termination
                of this Agreement. 

            

      

      	F.  	
              Payments
                due under this Agreement that are more than sixty (60) days late
                shall be
                subject to a twenty percent (20%) per annum interest
                charge.

            

       

             
        6. REQUISITIONS AND ACKNOWLEDGEMENTS

      

      	A.  	
              DNA
                Material Supply. The parties agree to jointly and continuously determine
                DNA material stockpile requirements sufficient to meet the production
                requirements of IIMAK. ADNAS shall stockpile in the US at a facility(s)
                selected by ADNAS and approved by IIMAK, sufficient DNA Materials
                to
                ensure at all times the adequate and on-time supply of DNA Material
                in
                quantities sufficient to fully meet the production requirements of
                IIMAK
                in a timely manner.

            

      

      	B.  	
              Delivery.
                ADNAS will use commercially reasonable efforts to deliver the ADNAS
                Materials at the times specified in its written acknowledgment of
                a
                requisition for ADNAS Materials. ADNAS will not be liable to IIMAK
                or to
                any other party for any delay in the delivery of the ADNAS Materials
                not
                directly attributable to ADNAS. 

            

      

      	C.  	
              Shipment.
                ADNAS will package and ship the ADNAS Materials in accordance with
                standard commercial practices. The ADNAS Materials will be shipped
                prepaid
                to the location specified on IIMAK’s requisition, by a mode of shipment
                selected by ADNAS. Title, except to the extent the ADNAS Materials
                contain
                or consist of software or firmware, will pass to IIMAK upon ADNAS’
                delivery of the ADNAS Materials to the facility site of IIMAK.
                

            

      

      	D.  	
              Ordering.
                All requisitions for ADNAS Materials submitted by IIMAK will be sent
                to
                ADNAS at the address set forth below, email address(es) or via facsimile.
                All requisitions will specify the type and quantity of the ADNAS
                Materials
                requested and the delivery date requested, and will be sent to the
                attention of Dr. Benjamin Liang with copies to MeiLin Wan and Kurt
                Jensen
                . All of IIMAK’s requisitions will be governed exclusively by the terms
                and conditions of this Agreement. 

            

      

      	E.  	
              Acceptance.
                A requisition will be confirmed or declined by ADNAS in writing,
                by email,
                or facsimile within five (5) business days of its
                receipt.

            

       

             
        7. MANUFACTURING, SALES AND MARKETING.

      

      	A.  	
              Upon
                successful completion of the Joint Development, IIMAK agrees to develop
                a
                Manufacturing, Sales & Marketing Plan to undertake manufacturing,
                sales and marketing efforts to promote the Products into the target
                markets and to target clients. The Manufacturing, Sales & Marketing
                Plan shall identify and prioritize clients, define product categories
                and
                applications, program marketing activities, news releases, trade
                show
                participation, web seminars and direct electronic mailing campaigns.
                IIMAK
                shall create industry-specific and customer-specific marketing and
                presentation Materials and shall mount comprehensive trade publicity
                programs for the Products as they are developed.
                

            

      
        
           

          
            
              
              

            

            
              5
                of
                12

              
                

              

            

            
              
              

            

          

           

        

      

      	B.  	
              Within
                the guidelines of the Manufacturing, Sales & Marketing Plan, each of
                the parties shall provide Technical Sales support to the other party
                and
                each shall make appropriate staff or Consultants available to participate
                in sales calls and meetings with target clients. Technical Sales
                support
                shall be provided by each party at its own cost, unless circumstances
                impose an undue burden upon one party, in which case the parties
                shall
                arrange cost-sharing as may be appropriate and such cost sharing
                shall be
                set forth in writing, and signed by both parties
                

            

       

             
        8. MATERIALS WARRANTY. 

      

      	A.  	
              ADNAS,
                at its expense, shall defend any suit brought against IIMAK on the
                grounds
                that use of the ADNAS Materials or DNA Technologies for the intended
                purpose or purposes, as furnished by ADNAS, infringes any United
                States
                patent and shall pay the amount of any judgment that may be awarded
                against IIMAK in any such suit provided and upon condition that IIMAK
                shall (a) promptly deliver to ADNAS all infringement notices and
                other
                papers received by or served upon IIMAK, (b) permit ADNAS to take
                charge
                of the defense of such suit and compromise the same, if deemed advisable
                by ADNAS, and (c) assist in every reasonable way in the conduct of
                such
                defense.

            

      

      	B.  	
              IIMAK,
                at its expense, shall defend any suit brought against ADNAS on the
                grounds
                that use of the Products for the intended purpose or purposes, infringes
                any United States patent and shall pay the amount of any judgment
                that may
                be awarded against ADNAS in any such suit provided and upon condition
                that
                ADNAS shall (a) promptly deliver to IIMAK all infringement notices
                and
                other papers received by or served upon ADNAS, (b) permit IIMAK to
                take
                charge of the defense of such suit and compromise the same, if deemed
                advisable by IIMAK, and (c) assist in every reasonable way in the
                conduct
                of such defense. 

            

      

      	C.  	
              In
                the event that IIMAK shall be enjoined by a court of competent
                jurisdiction from which no appeal can be taken, from selling or using
                the
                Products for the intended purpose or purposes on the ground that
                such sale
                or use of the Product infringes any such United States or other patent,
                or
                it is established to ADNAS satisfaction, upon due investigation,
                that sale
                or use of the Product infringes any such United States or other patent,
                ADNAS at its option may either (i) procure for IIMAK a license to
                sell
                and/or use the Products, (ii) modify the Products so as to make it
                non-infringing without seriously impairing its performance, (iii)
                replace
                the Products with a product that is substantially equal but
                non-infringing, or (iv) accept the return of the Product from IIMAK.
                

            

      

      	D.  	
              ADNAS
                shall be responsible for assuring and insuring the integrity of any
                patent
                or trademark application process regarding the ADNAS Materials and
                for
                safeguarding by reasonable measures the confidentiality of all proprietary
                or trade secret information related to the ADNAS Materials to be
                used as
                components in the Products.

            

      
         

        
          
            
            

          

          
            6
              of
              12

            
              

            

          

          
            
            

          

        

         

      

      	E.  	
              ADNAS
                shall supply to IIMAK technical specifications for the ADNAS Materials
                including, but not limited to, MSDS data, suitability for commercial
                use,
                stability in environmental and application conditions, safety for
                use in
                products exposed to the skin or general human occupational and end-use
                product exposure, technologies, methods and materials for successful
                analysis of the DNA component of the products, and specifications
                for use
                in marketing materials that describe the characteristics of the ADNAS
                Materials. 

            

      

      	F.  	
              IIMAK
                shall be responsible for assuring and insuring the integrity of any
                patent
                or trademark application process regarding the IIMAK materials and
                for
                safeguarding by reasonable measures the confidentiality of all proprietary
                or trade secret information related to the IIMAK Materials to be
                used as
                components in the Products.

            

      

      	G.  	
              ADNAS
                shall secure Insurance for the Loss of Goods in Transit together
                with
                coverage against damages that may arise there from, for the ADNAS
                materials.

            

      

      	H.  	
              IIMAK
                shall secure Insurance for the Loss of Goods in Transit to end users(s)
                together with coverage against damages that may arise therefrom,
                for the
                IIMAK materials and the Products.

            

      

      	I.  	
              Each
                party shall be responsible for acquiring and/or maintaining Product
                Liability Insurance and shall provide documentation of such insurance
                or
                other financial responsibility, upon demand of the other
                party.

            

      

      	J.  	
              ADNAS
                and IIMAK shall jointly determine Warranty and shelf-life limitations.
                

            

       

             
        9. CONFIDENTIALITY.

       

      	A.  	
              The
                Parties recognize that each party shall disclose to the other information
                concerning suppliers, clients, distributors, agents, brokers, buyers,
                sellers, technical data, performance data, pricing details, formulas,
                processes, commissions, discounts, information relating to competitors
                and
                other information which the parties have acquired through their investment
                of time, expense and effort and which may constitute confidential
                proprietary business information, intellectual property, and/or trade
                secrets. The parties acknowledge and agree that during the term of
                this
                Agreement, and in the course of the discharge of the duties hereunder,
                the
                parties shall have access to and become acquainted with information
                concerning the operation of the other party, including, financial,
                personnel, sales, manufacturing, buying, planning, and other information
                owned by and regularly used in the operation of the business of each
                party
                and each party shall also receive information of a proprietary nature
                regarding the constitution, formulation, pricing and effectiveness
                of the
                Products and both parties hereto accept that such information as
                outlined
                above constitutes the Confidential Information of the providing
                party.

            

      
         

        
          
            
            

          

          
            7
              of
              12

            
              

            

          

          
            
            

          

        

         

      

      	B.  	
              As
                used herein, “Confidential Information” of a party means all trade secret,
                proprietary and confidential information and materials, in any form
                whatever, relating to such party’s technologies, compounds, research
                programs, operations or financial or business condition (including,
                without limitation, know-how, data, drawings, designs, specifications,
                formulations, processes, methods, equipment, software and pricing
                information) that is (i) disclosed in writing and marked as
                “Confidential”, “Proprietary” or with similar words, or (ii) orally
                or visually disclosed and identified as confidential or proprietary
                at the
                time of disclosure and confirmed as such in writing within thirty
                (30)
                days thereafter.

            

      

      	C.  	
              Notwithstanding
                Section 9A or 9B above, “Confidential Information” of a party shall not
                include any information or materials
                that:

            

      

      	a)  	
              are
                approved for release by that party in writing without
                restriction;

            

      

      	b)  	
              are
                demonstrated by written records of the receiving party as being previously
                known to it other than through a prior disclosure by the disclosing
                party
                or by any third party with an obligation of confidentiality to the
                disclosing party;

            

      

      	c)  	
              are
                publicly known as of the date of this Agreement, or become public
                knowledge subsequent thereto, through no act or omission of the party
                receiving the information or any third party with an obligation of
                confidentiality to such party;

            

      

      	d)  	
              are
                obtained by the receiving party in good faith from a third party
                without
                the violation of any obligation of confidentiality to such party
                by either
                the receiving party or such third party;
                or

            

      

      	e)  	
              are
                independently developed by or on behalf of the receiving party without
                the
                benefit of such party’s Confidential Information, as shown by competent
                written records.

            

       

      10.
        NON-CIRCUMVENTION AND NON-COMPETITION.

      

      	A.  	
              In
                Consideration of this Agreement each party agrees not to attempt
                in any
                manner to commercially exploit, either directly or indirectly, the
                proprietary business concepts and Technologies or any of the Confidential
                Information without the other party’s prior written consent. The parties
                specifically understand and agree that this prohibition is specifically
                intended to include any direct or indirect solicitation of the other’s
                customer/client contacts by either party’s then current Providers,
                Suppliers, Agents, Employees and/or
                Representatives.

            

      
         

        
          
            
            

          

          
            8
              of
              12

            
              

            

          

          
            
            

          

        

         

      

      11.
        CHOICE
        OF LAW AND JURISDICTION.

      

      This
        Agreement and all amendments, modifications, alterations or supplements hereto,
        and the rights of all Parties hereunder, shall be construed under and governed
        by the laws of the State of New York, U.S.A. (without regard to its laws
        regarding choice of law) and the United States f America. Only federal or
        state
        courts located in the State of New York, U.S.A. shall have jurisdiction to
        hear
        and decide any controversy or claim between the Parties arising under or
        relating to this Agreement.

      Arbitration

      Any
        disputes, controversies or claims arising out of this Agreement shall be
        resolved through arbitration conducted under the auspices of the American
        Arbitration Association pursuant to that organization’s rules for commercial
        arbitration.

      

      12. NOTICES.

      

      All
        notices, demands and other communications to be given or delivered under
        or by
        reason of the provisions of this Agreement shall be given in writing and
        may be
        addressed as follows:

      

      Applied
        DNA Sciences, Inc.

      Att’n:
        Kurt Jensen

      25
        Health
        Sciences Dr 

      Stony
        Brook NY 11790 

      Tel:
        631-444-6370

      Fax:
        631-444-8848

      

      Copy
        to:

      

      Joe
        Daniels

      Fulbright
        & Jaworski

      666
        Fifth
        Avenue

      New
        York,
        New York 10103

      Tel:
        212
        318-3322

      Fax:
        212
        318-3400

      

      IIMAK

      Att’n
        Daniel J. Harrison

      310
        Commerce Dr.

      Amhert,
        NY 14228

      Tel:
        716
        691 6333 x2423

      Fax:
        716
        531 7152

      

      

      Copy
        to:

      

      IIMAK

      Att’n
        Tony Ryder, CFO

      310
        Commerce Dr.

      Amherst,
        NY 14228

      Tel:
        716 691 6333 x 2260

      Fax:
        716 691 1133

      
         

        
          
            
            

          

          
            9
              of
              12

            
              

            

          

          
            
            

          

        

         

      

      All
        written notices and responses required herein may be made by certified mail,
        overnight carrier service or e-mail, and must be supported by a record of
        delivery and receipt.

      

      13.
        COMPLETE AGREEMENT.

      

      This
        Agreement constitutes the complete and exclusive statement of understanding
        among the Parties. It supersedes all prior written or oral statements, including
        any prior representation, statement, condition, or warranty, except as expressly
        provided otherwise herein. This Agreement may not be amended without the
        written
        consent of all of the Parties and represents a final agreement of the parties.
        No change or modification of this Agreement shall be valid unless the same
        be in
        writing and signed by all parties hereto and attached hereto as a supplement
        and
        made an integral part of this Agreement.

      

      14.
        TERMINATION AND VOIDABILITY.

      

      In
        the
        event any party hereto becomes insolvent as evidenced by the filing of any
        petition in bankruptcy, the appointment of a receiver, or has its business
        activity suspended or curtailed as a result of any criminal prosecution or
        imposition of any civil penalty by a court of competent jurisdiction for
        violation of e.g.,
        the
        securities or anti-trust laws of the United States or any state thereof,
        then
        this Agreement shall be voidable in the sole discretion of the other party.
        

      

      Termination
        for Material Breach

      If
        either
        Party breaches a material obligation under this Agreement, the other party
        shall
        have the right to give the breaching Party written notice describing the
        alleged
        breach. If the breaching Party does not cure such breach within ninety (90)
        days
        after receipt of such notice, the notifying Party may, in addition to any
        other
        rights it may have under this Agreement, terminate this Agreement effective
        immediately. However, if there is a dispute between the Parties as to
        termination under this Section 14, no termination shall be effected until
        such
        dispute is resolved pursuant to Section 11.

      

      15.
        EQUITABLE RELIEF.

      

      The
        Parties acknowledge that a violation or threatened violation of this Agreement
        or any of its provisions may cause irreparable injury; that the Agreement
        concerns unique and special materials, properties and processes, and that
        money
        damages alone would be an inadequate remedy; and that, in addition to any
        other
        remedies available at law or in equity, such a violation or threatened violation
        of this Agreement or any of its provisions may be subject to a restraining
        order, injunctive relief, a decree of specific performance or other similar
        remedy in order to specifically enforce the provisions of this
        Agreement.

      

      16.
        MISCELLANEOUS.

      

      Waiver
        of Breach. The
        waiver by a party of a breach of any provision of this Agreement by the other
        party shall not operate or be construed as a waiver of any subsequent
        breach.

      
         

        
          
            
            

          

          
            10
              of
              12

            
              

            

          

          
            
            

          

        

         

      

      Counterparts.
        This
        Agreement may be executed in counterparts, each of which shall be deemed
        an
        original and together shall constitute one and the same agreement.

      

      Partial
        Validity.  The terms contained in this Agreement are
        considered reasonable by the parties, but in the event that any provision
        shall
        be found to be void but would be valid if some part thereof were deleted,
        or the
        period or area of application reduced, such restriction shall apply with
        such
        modification as may be necessary to make it valid and effective. Each provision
        of this Agreement shall be considered separable; and if, for any reason,
        any
        provision or provisions herein are determined to be invalid and contrary
        to any
        existing or future law, such invalidity shall not impair the operation of
        or
        affect those portions of this Agreement which are valid.

      

      Legal
        Compliance. IIMAK
        shall comply with all laws and regulations relating to its manufacture, use,
        sale, labeling or distribution of Products and shall not take any action
        which
        would cause ADNAS or IIMAK to violate any applicable laws or
        regulation.

      

      Independent
        Contractor. Neither Party shall be considered to be an
        employee or agent of the other, nor shall this Agreement constitute, create
        or
        in any way be interpreted as a formal business organization of any kind.
        In that
        respect, neither Party shall have the authority to execute any agreement
        on
        behalf of the other Party, nor shall either Party have any authority to
        negotiate any agreement, except as the other Party may expressly direct in
        writing.

      

      Force
        Majeure.  Any delays in, or failure of, performance of any
        Party to this Agreement shall not constitute a default hereunder, or give
        rise
        to any claim for damages, if and to the extent caused by occurrences beyond
        the
        control of the Party affected, including, but not limited to, acts of God,
        acts
        of terrorism, strikes or other concerted acts of workmen, civil disturbances,
        fires, floods, earthquakes, explosions, riots, war, rebellion, sabotage,
        acts of
        governmental authority or failure of governmental authority to issue licenses
        or
        approvals which may be required.

      
        
           

          
            
              
              

            

            
              11
                of
                12

              
                

              

            

            
              
              

            

          

           

        

      

      Binding
        Effect.
        This Agreement shall be binding upon and shall inure to the benefit of the
        parties hereto and their respective successors, assigns, heirs, and personal
        representatives.

       

      Sections,
        Subtitles, and Captions.
        Whenever reference is made to a section of this Agreement by a single number
        without decimals, such reference shall include all decimal sections bearing
        the
        same principal number. Subtitles and paragraph captions are inserted for
        convenience of reference and do not constitute part of the
        Agreement.

       

      Construction.
        In
        construing this Agreement, plural terms shall be substituted for singular
        and
        singular for plural in any place in which the context so requires.

       

      Authority
        to Contract.
        Both
        parties hereto warrant that they are validly organized corporations, in good
        standing under the laws of their states of incorporation, and have the authority
        to enter into this Agreement.

       

      Disclosure.
        Announcements of this Agreement may be made to the public with the mutual
        consent of both parties, which consent shall not be unreasonably withheld.
        The
        announcing party will provide the other party with a draft of the announcement
        as soon as possible prior to the announcement date. Both parties will negotiate
        in good faith with each other regarding the content of the announcement and
        will
        use reasonable efforts to reach agreement on the content of the announcement
        before it is made public. Notice of any press release, public statement or
        public disclosure which is mandated by law shall be furnished to the other
        party
        as far in advance as is reasonably possible and its input shall be taken
        into
        account with respect thereto to the extent not inconsistent with such legal
        obligation.

       

       

      IN
        WITNESS WHEREOF, each of the Parties below has caused this Agreement to be
        executed by its duly authorized representatives on this 18 day of April,
        2007.

       

      

        
          	
                  For
                    ADNAS by:

                	 	 
	 	 	 
	
                  /s/Kurt
                    Jensen

                	 	 
	
                  Name:
                    Kurt Jensen

                	 	 
	
                  Title:
                    Comptroller

                	 	 
	 	 	 
	 	 	 
	
                  For
                    IIMAK by:

                	 	 
	 	 	 
	/s/
                  Daniel J. Harrison	 	4/19/2007
	
                  Name:
                     Daniel
                    J. Harrison

                	 	 
	
                  Title:
                     Vice
                    President, R&D

                	 	 

        

      

       

      
12
        of 12Exhibit 10.2

    
      

    

    Exhibit
      10.2

    

      APPLIED
        DNA SCIENCES, INC. 

      

      Applied
        DNA Sciences, Inc., a Nevada corporation (the “Company”), hereby certifies that,
        for value received, ______________ (the “Warrant Holder,” which term includes
        its successors and registered assigns) is entitled to purchase an aggregate
        of
        200,000 shares of common stock, par value $0.001 per share, of the Company
        (the
“Common Stock”) at an exercise price of $0.50 per share (the “Exercise Price”)
        per share.

      

      1.     Exercise
        of Warrant.
        This
        Warrant may be exercised in whole or in part at any time or from time to
        time
        during the four year period commencing on April 23, 2008 and expiring at
        5:00
        p.m., New York City time, on April 22, 2012 (the “Exercise Term”), or if such
        day is a day on which banking institutions in the State of New York are
        authorized by law to close, then on the next succeeding day which shall not
        be
        such a day, as follows:

      

      (a)    by
        presentation and surrender of this Warrant evidencing the Warrant to be
        exercised to the Company at its principal office or at the office of its
        stock
        transfer agent, if any, with the Exercise Form annexed hereto duly executed,
        and
        payment of the Exercise Price; or 

      

      (b)    by
        presentation and surrender of this Warrant evidencing the Warrant to be
        exercised to the Company at its principal office or at the office of its
        stock
        transfer agent, if any, with the Exercise Form annexed hereto duly executed,
        in
        which event the Company shall issue to the Warrant Holder the number of shares
        of Common Stock underlying this Warrant (the “Warrant Shares”) determined based
        on the following formula: 

      

      X
        =
        Y*(A-B)/A

      

      where:

      

      X
        means
        the number of Warrant Shares to be issued to the Warrant Holder.

      

      Y
        means
        the number of Warrant Shares with respect to which this Warrant is being
        exercised.

      

      A
        means
        the fair market value of one share of Common Stock as determined in accordance
        with the provisions of this Section.

      

      B
        means
        the Exercise Price.

      

      The
“fair
        market value” of one share of Common Stock means the average of the closing bid
        prices of the Common Stock on The Over The Counter Bulletin Board or any
        national securities exchange on trading days during the 12 months immediately
        preceding the effective date of exercise of the Warrant and, if there is
        no
        active public market for the Common Stock, the fair market value shall be
        the
        price determined in good faith by the Board of Directors of the Company.
        

      

      If
        any
        Warrant should be exercised in part only, the Company shall, upon surrender
        of
        this Warrant for cancellation and presentment of the Exercise Form, execute
        and
        deliver new a Warrant or Warrants, as the case may be, evidencing the rights
        of
        the Warrant Holder thereof to purchase the balance of the shares purchasable
        thereunder.

      
        
          
          

        

        
          1

          
            

          

        

        
          
          

        

      

       

      Upon
        receipt by the Company of this Warrant at its office, or by the stock transfer
        agent of the Company at its office, in proper form for exercise together
        with
        the payment of the Exercise Price, unless this Warrant is being exercised
        pursuant to the cashless exercise option, in which case no payment is required,
        the Warrant Holder shall be deemed to be the holder of record of the Warrant
        Shares, notwithstanding that the stock transfer books of the Company shall
        then
        be closed or that certificates representing such Warrant Shares shall not
        then
        be actually delivered to the Warrant Holder. Certificates for the Warrant
        Shares
        shall be delivered to the Warrant Holder within a reasonable time following
        the
        exercise of this Warrant in accordance with the foregoing. 

      

      2.     Alternative
        Exercise Provisions.
        Anything contained herein to the contrary notwithstanding, subject to compliance
        by the Warrant Holder with the restrictions on offer and sale referred to
        in
        Section 11 hereof, the Warrant Holder, at its option, may exercise this Warrant,
        in whole or in part, during the Exercise Term by delivering to the Company
        a
        confirmation slip issued by a brokerage firm that is a member of the National
        Association of Securities Dealers, Inc. or the equivalent governing body
        for
        broker-dealers in other nations, with respect to the sale of those number
        of
        Warrant Shares for which this Warrant is being exercised, together with the
        payment of the Exercise Price, unless this Warrant is being exercised pursuant
        to the cashless exercise option, in which case no payment is required, and,
        in
        such case, the Company shall deliver certificates representing such Warrant
        Shares on settlement date at the office of the Company’s stock transfer agent.

      

      3.     Reservation
        and Listing of Shares.
        The
        Company hereby agrees that at all times there shall be reserved for issuance
        and
        delivery upon exercise of this Warrant, such number of shares of its Common
        Stock as shall be required for issuance and delivery upon exercise of this
        Warrant. As long as this Warrant is outstanding, the Company shall use its
        best
        efforts to cause all shares of Common Stock issuable upon the exercise of
        this
        Warrant to be listed on The Over The Counter Bulletin Board or on NASDAQ
        or a
        national securities exchange, if such shares of Common Stock, as a class,
        are
        theretofore so listed. 

      

      4.     Fractional
        Shares.
        No
        fractional shares or scrip representing fractional shares shall be issued
        upon
        the exercise of this Warrant. Any fraction of a share called for upon any
        exercise hereof shall be canceled. The Warrant Holder, by his acceptance
        hereof,
        expressly waives any right to receive any fractional share of stock or
        fractional Warrant upon exercise of this Warrant. 

      

      5.     Exchange,
        Transfer, Assignment or Loss of Warrant.
        This
        Warrant is exchangeable, without expense, at the option of the Warrant Holder,
        upon presentation and surrender of this Warrant evidencing such Warrants
        to the
        Company at its office or at the office of its stock transfer agent, if any,
        for
        other Warrants of different denominations entitling the Warrant Holder thereof
        to purchase in the aggregate the same number of shares of Common Stock as
        are
        purchasable thereunder at the same respective Exercise Price. Subject to
        Section
        11 hereof, upon surrender of this Warrant to the Company at its principal
        office
        or at the office of its stock transfer agent, if any, with a duly executed
        assignment form and funds sufficient to pay the applicable transfer tax,
        if any,
        the Company shall, without charge, execute and deliver new Warrant(s) in
        the
        name of the assignee named in such instrument of assignment and the original
        Warrant shall promptly be canceled. This Warrant may be divided or combined
        with
        other Warrants which carry the same rights upon presentation of this Warrant
        at
        the office of the Company or at the office of its stock
        transfer

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

      agent,
        if
        any, together with a written notice signed by the Warrant Holder hereof
        specifying the names and denominations in which new Warrants are to be issued.
        Upon receipt by the Company of evidence satisfactory to it of the loss, theft,
        destruction or mutilation of this Warrant, and, in the case of loss, theft
        or
        destruction, of reasonably satisfactory indemnification, and upon surrender
        and
        cancellation of this Warrant, if mutilated, the Company will execute and
        deliver
        new Warrants of like tenor and date. 

      

      6.     Rights
        of the Warrant Holder.
        The
        Warrant Holder shall not, by virtue hereof, be entitled to any rights of
        a share
        holder of the Company until exercise of any Warrants. 

      

      7.     Adjustments
        of Purchase Price and Number of Shares.
        

      

      (a)     Subdivision
        and Combination.
        If the
        Company shall at any time subdivide or combine the outstanding shares of
        Common
        Stock by way of stock split, reverse stock split or the like, the Exercise
        Price
        shall forthwith be proportionately increased or decreased. 

      

      (b)     Adjustment
        in Number of Shares.
        Upon
        each adjustment of the Exercise Price pursuant to the provisions of paragraph
        7(a), the number of shares of Common Stock issuable upon the exercise of
        this
        Warrant shall be adjusted to the nearest full share of Common Stock by
        multiplying a number equal to the Exercise Price in effect immediately prior
        to
        such adjustment by the number of shares of Common Stock issuable upon exercise
        of this Warrant immediately prior to such adjustment and dividing the product
        so
        obtained by the adjusted Exercise Price. 

      

      (c)     Reclassification,
        Consolidation, Merger, etc.
        In case
        of any reclassification or change of the outstanding shares of Common Stock
        (other than a change in par value to no par value, or from no par value to
        par
        value, or as a result of a subdivision or combination), or in the case of
        any
        consolidation of the Company with, or merger of the Company into, another
        corporation (other than a consolidation or merger in which the Company is
        the
        surviving corporation and which does not result in any reclassification or
        change of the outstanding shares of Common Stock, except a change as a result
        of
        a subdivision or combination of such shares or a change in par value, as
        aforesaid), or in the case of a sale or conveyance to another corporation
        of all
        or a substantial part of the property of the Company, the Warrant Holder
        shall
        thereafter have the right to purchase the kind and number of shares of stock
        and
        other securities and property receivable upon such reclassification, change,
        consolidation, merger, sale or conveyance as if the Warrant Holder were the
        owner of the shares of Common Stock underlying this Warrant immediately prior
        to
        any such events at a price equal to the product of (x) the number of shares
        issuable upon exercise of this Warrant and (y) the Exercise Price in effect
        immediately prior to the record date for such reclassification, change,
        consolidation, merger, sale or conveyance as if such Warrant Holder had
        exercised this Warrant. 

      

      (d)     Dividends
        and Other Distributions with Respect to Outstanding Securities.
        In the
        event that the Company shall at any time prior to the exercise of all Warrants
        declare a dividend (other than a dividend consisting solely of shares of
        Common
        Stock or a cash dividend or distribution payable out of current or retained
        earnings) or otherwise distribute to the holders of its Common Stock any
        monies,
        assets, property, rights, evidences of indebtedness, securities (other than
        shares of Common Stock), whether issued by the Company or by another person
        or
        entity, or any other thing of value, the Warrant 

      
        
          
          

        

        
          3

          
            

          

        

        
          
          

        

      

      Holder
        of
        the unexercised Warrants shall thereafter be entitled, in addition to the
        shares
        of Common Stock or other securities receivable upon the exercise thereof,
        to
        receive, upon the exercise of such Warrants, the same monies, property, assets,
        rights, evidences of indebtedness, securities or any other thing of value
        that
        they would have been entitled to receive at the time of such dividend or
        distribution. At the time of any such dividend or distribution, the Company
        shall make appropriate reserves to ensure the timely performance of the
        provisions of this Subsection 7(e). 

      

      (e)     Warrant
        After Adjustment.
        Irrespective of any change pursuant to this Section 7 in the Exercise Price
        or
        in the number, kind or class of shares or other securities or other property
        obtainable upon exercise of this Warrant, this Warrant may continue to express
        as the Exercise Price and as the number of shares obtainable upon exercise,
        the
        same price and number of shares as are stated herein. 

      

      (f)     Statement
        of Calculation.
        Whenever the Exercise Price shall be adjusted pursuant to the provisions
        of this
        Section 7, the Company shall forthwith file at its principal office, a statement
        signed by an executive officer of the Company specifying the adjusted Exercise
        Price determined as above provided in such section. Such statement shall
        show in
        reasonable detail the method of calculation of such adjustment and the facts
        requiring the adjustment and upon which the calculation is based. The Company
        shall forthwith cause a notice setting forth the adjusted Exercise Price
        to be
        sent by certified mail, return receipt requested, postage prepaid, to the
        Warrant Holder. 

      

      8.     Redemption
        Rights.
        This
        Warrant may be redeemed at the option of the Company at a redemption price
        equal
        to $0.01 at any time subsequent to the earlier of (i) the date three years
        from
        the date of the first issuance and sale of this Warrant and (ii) the date
        that
        the Common Stock has traded on The Over the Counter Bulletin Board at or
        above
        $1.00 per share for 20 consecutive trading days. The Company may exercise
        this
        right of redemption by written notice to the Warrant Holder together with
        payment of the redemption price. 

      

      9.     Definition
        of “Common Stock”.
        For the
        purpose of this Warrant, the term “Common Stock” shall mean, in addition to the
        class of stock designated as the Common Stock, $.001 par value, of the Company
        on the date hereof, any class of stock resulting from successive changes
        or
        reclassifications of the Common Stock consisting solely of changes in par
        value,
        or from par value to no par value, or from no par value to par value. If
        at any
        time, as a result of an adjustment made pursuant to one or more of the
        provisions of Section 7 hereof, the shares of stock or other securities or
        property obtainable upon exercise of this Warrant shall include securities
        of
        the Company other than shares of Common Stock or securities of another
        corporation, then thereafter the amount of such other securities so obtainable
        shall be subject to adjustment from time to time in a manner and upon terms
        as
        nearly equivalent as practicable to the provisions with respect to Common
        Stock
        contained in Section 7 hereof and all other provisions of this Warrant with
        respect to Common Stock shall apply on like terms to any such other shares
        or
        other securities. 

      

      10.    Reserved.

      

      11.    Restrictions
        on Offer and Sale.
        THE
        OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
        WITH OR APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE
        COMMISSION OR ANY SECURITIES COMMISSION OR REGULATORY AUTHORITY AND ARE BEING
        OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE
        ACT.

      
        
          
          

        

        
          4

          
            

          

        

        
          
          

        

      

      

      THE
        SALE,
        ASSIGNMENT, CONVEYANCE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES
        REPRESENTED BY THIS WARRANT IS PROHIBITED EXCEPT (1) PURSUANT TO REGISTRATION
        UNDER THE ACT; OR (2) PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
        UNDER
        THE ACT, AND ANY CERTIFICATE REPRESENTING WARRANT SHARES SHALL BEAR A LEGEND
        TO
        SUCH EFFECT. 

      

      12.    Notices
        to Warrant Holder.
        Nothing
        contained in this Warrant shall be construed as conferring upon the Warrant
        Holder the right to vote or to consent or to receive notice as a shareholder
        in
        respect of any meetings of shareholders for the election of directors or
        any
        other matter, or as having any rights whatsoever as a share holder of the
        Company. If, however, at any time prior to the expiration of this Warrant
        and
        its exercise, any of the following events shall occur: 

      

      (a)    The
        Company shall take a record of the holders of its shares of Common Stock
        for the
        purpose of entitling them to receive a dividend or distribution payable
        otherwise than in cash, or a cash dividend or distribution payable otherwise
        than out of current or retained earnings, as indicated by the accounting
        treatment of such dividend or distribution on the books of the Company; or
        

      

      (b)    The
        Company shall offer to all the holders of its Common Stock any additional
        shares
        of capital stock of the Company or securities convertible into or exchangeable
        for shares of capital stock of the Company, or any warrant, right or option
        to
        subscribe therefor; or 

      

      (c)     A
        dissolution, liquidation or winding up of the Company (other than in connection
        with a consolidation or merger) or a sale of all or substantially all of
        its
        property, assets and business shall be proposed; or 

      

      (d)    There
        shall be any capital reorganization or reclassification of the capital stock
        of
        the Company, or consolidation or merger of the Company with another entity;
        then, in anyone or more of said events, the Company shall give written notice
        of
        such event at least fifteen (15) days prior to the date fixed as a record
        date
        or the date of closing the transfer books for the determination of the
        shareholders entitled to such dividend, distribution, convertible or
        exchangeable securities or subscription rights, warrants or options, or entitled
        to vote on such proposed dissolution, liquidation, winding up or sale. Such
        notice shall specify such record date or the date of closing the transfer
        books,
        as the case may be. Failure to give such notice or any defect therein shall
        not
        affect the validity of any action taken in connection with the declaration
        or
        payment of any such dividend or distribution, or the issuance of any convertible
        or exchangeable securities or subscription rights, warrants or options, or
        any
        proposed dissolution, liquidation, winding up or sale. 

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

      

       

      13.    Notices.
        

      

      (a)     All
        communications under this Warrant shall be in writing and shall be mailed
        by
        certified mail, postage prepaid, return receipt requested, or telecopied
        with
        confirmation of receipt or delivered by hand or by overnight delivery service:
        

      

      
        	
                If
                  to the Company at:

              	
                Applied
                  DNA Sciences, Inc.

              
	 	
                Attn:
                  Jim Hayward, Chief Executive Officer 

              
	 	
                25
                  Health Sciences Drive, Suite 113 

              
	 	
                Stony
                  Brook, New York 11790 

              

      

      

      If
        to the
        Warrant Holder, to the address of such Warrant Holder as it appears in the
        stock
        or warrant ledger of the Company. 

      

      (b)     Any
        notice so addressed, when mailed by registered or certified mail shall be
        deemed
        to be given three days after so mailed, when telecopied shall be deemed to
        be
        given when transmitted, or when delivered by hand or overnight shall be deemed
        to be given when hand delivered or on the day following deposit with the
        overnight delivery service. 

      

      14.    Successors.
        All the
        covenants and provisions of this Warrant by or for the benefit of the Warrant
        Holder shall inure to the benefit of his successors and assigns hereunder.
        

      

      15.    Termination.
        This
        Warrant will terminate on the earlier of (a) the expiration date of this
        Warrant
        or (b) the date this Warrant has been exercised. 

      

      16.    Governing
        Law.
        This
        Warrant shall be deemed to be made under the laws of the State of New York
        and
        for all purposes shall be construed in accordance with the laws of said State,
        excluding choice of law principles thereof. 

      

      17.    Entire
        Agreement, Amendment, Waiver.
        This
        Warrant and all attachments hereto and all incorporation by references set
        forth
        herein, set forth the entire agreement and understanding between the parties
        as
        to the subject matter hereof and merges and supersedes all prior discussions,
        agreements and understandings of any and every nature among them. This Warrant
        may be amended, the Company may take any action herein prohibited or omit
        to
        take any action herein required to be performed by it, and any breach of
        any
        covenant, agreement, warranty or representation may be waived, only if the
        Company has obtained the written consent or waiver of the Warrant Holder.
        No
        course of dealing between or among any persons having any interest in this
        Warrant will be deemed effective to modify, amend or discharge any part of
        this
        Warrant or any rights or obligations of any person under or by reason of
        this
        Warrant. 

      

      

      

      THIS
        SPACE INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOLLOWS 

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

      

      IN
        WITNESS WHEREOF,
        the
        undersigned has executed this Warrant as of this 23rd
        day of
        April, 2007.

      

      

      
        
          	 	
                  APPLIED DNA SCIENCES, INC.

                  
                     

                     

                    By:
                      /s/ James A.
                      Hayward                          
                      

                    Name:
                      James A. Hayward

                    Title:
                      Chief Executive Officer

                  

                

        

      

      

      

      

      

      

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

      

      

      APPLIED
        DNA SCIENCES, INC.

       

      WARRANT
        ASSIGNMENT FORM

       

      (To
        be
        signed only upon assignment of Warrant)

       

      

      FOR
        VALUE
        RECEIVED, the undersigned hereby sells, assigns and transfers unto

       

      
        
          

        

         

      

      
        

      

       

      
        

      

       (Name
        and
        address of assignee must be printed or typewritten)

      

      the
        rights of the undersigned with respect to the Warrant surrendered herewith
        to
        the extent
        of 
        ( )
        shares
        of
        Common Stock, $.001 par value per share,
        of
        Applied DNA Sciences, Inc. (the “Company”), hereby irrevocably constituting and
appointing ,
        attorney
        to make such transfer on the books of the Company, with full power of
        substitution in the premises.

      

      

        
          	
                  Dated:_______________________________

                	
                
	 	
                  
                    

                  

                  Signature
                    of Registered Holder

                
	 	 
	
                  Signature(s)
                    Guaranteed:

                	 
	
                   

                   

                	
                  
                    

                  

                  Signature
                    of Registered Holder, 

                  if
                    more
                    than one

                
	
                  

                	 
	 	
                  
                    

                  

                  Name
                    of Registered Holder

                   

                
	 	
                  
                    

                  

                  Name
                    of Registered Holder, if more than
                    one

                

        

      
        	
              	Note:	
                The
                  above signature(s) must correspond with the name(s) as it
                  (they)
                  appear(s) upon the Warrant in every particular, without alteration
                  or
                  enlargement or any change
                  whatever.

              

      

      

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

      

      APPLIED
        DNA SCIENCES, INC. 

      

      WARRANT
        EXERCISE FORM 

      

      (To
        be
        executed upon exercise Warrant) 

      

      The
        undersigned, the record holder of this Warrant, hereby irrevocably elects
        to
        exercise the right, represented by this Warrant, to purchase ___ of the Warrant
        Shares. 

      

      The
        undersigned requests that a certificate for the Warrant Shares being purchased
        be registered in the name of ______________ and that such certificate be
        delivered to __________. 

      

      

      
        	
                Dated:_____________
                  

              	 
	 	
                 

                
                  
(Signature)

              
	 	 
	 	 
	 	 
	 	
                
                  

                

                (Printed
                  Name)

              

      

      

      

      

      

      

      

      9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]